CEACAM5 and non-small cell lung carcinoma: CEA, Cyfra21‐1, and NSE were the most commonly measured within 3 months before first diagnosis with approximately 65% in NSCLC and 80% in SCLC, and ProGRP had the lowest utilization (around 30%).